MedTrace Logo

Effect of Androgel on Type 2 Diabetic Males With Hypogonadism

NCT00350701 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 49

Last updated 2022-02-10

Study results available
· View outcomes & findings →

Summary

This is to study the effect of replacing testosterone on different inflammatory cells in type 2 diabetics with low testosterone levels.

Conditions

  • Diabetes Mellitus Type 2

Interventions

DRUG

androgel

androgel 5g

DRUG

androgel 10g

androgel 10g

DRUG

placebo

placebo

Sponsors & Collaborators

  • Solvay Pharmaceuticals

    collaborator INDUSTRY

  • University at Buffalo

    lead OTHER

Principal Investigators

  • Paresh Dandona, MD · Kaleida Health/Diabetes Endocrinology Center of WNY

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
35 Years
Max Age
75 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-07-31
Primary Completion
2013-06-30
Completion
2013-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00350701 on ClinicalTrials.gov